文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

非酒精性脂肪性肝炎肝硬化患者前瞻性队列中的血液细菌DNA特征

Blood bacterial DNA signatures in a prospective cohort of patients with MASLD cirrhosis.

作者信息

Kwan Suet-Ying, Dolapchiev Lillian I, Sanchez Caren I, Calderone Tiffany L, Sanchez Jessica I, Bhongade Megha B, El Sabagh Ahmed, Cleere Darrel W, Gupta Nakul, Jalal Prasun K, Victor David W, Beretta Laura

机构信息

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Margaret M. and Albert B. Alkek Department of Medicine, Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas, USA.

出版信息

Hepatol Commun. 2025 Jun 9;9(7). doi: 10.1097/HC9.0000000000000722. eCollection 2025 Jul 1.


DOI:10.1097/HC9.0000000000000722
PMID:40489758
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12150986/
Abstract

BACKGROUND: Predictive biomarkers are needed to identify individuals with metabolic dysfunction-associated steatotic liver disease (MASLD), at high risk for HCC. Our study aimed to determine whether the detection of circulating bacterial DNA could be associated with HCC development in MASLD patients with liver cirrhosis. METHODS: We developed a multicenter prospective cohort of patients with cirrhosis undergoing surveillance for HCC by contrast-enhanced magnetic resonance imaging. In a nested cohort study, we performed 16S rRNA sequencing of cell-free DNA extracted from 343 longitudinal plasma samples collected from 151 MASLD patients with cirrhosis. Among the 151 patients, 25 developed HCC during follow-up. RESULTS: Following in silico decontamination approaches, variations in circulating bacterial DNA profiles were significantly associated with HCC development, cirrhosis severity, and male gender. Many of the identified taxa were well-known human-associated bacteria. Patients who developed HCC during follow-up showed an enrichment in Tsukamurella and Bacteroides, and depletion of Natronomonas. Associations with HCC development remained for the identified bacteria, after adjusting for cirrhosis severity and male gender. Acidobacteriota, Tsukamurella, and Staphylococcaceae showed markedly improved prediction of HCC within 12 months prior to diagnosis [Acidobacteriota: AOR=2.87 (1.36-6.04), p=0.006; Tsukamurella: AOR=2.80 (1.34-5.85), p=0.006; Staphylococcaceae: AOR=2.52 (1.19-5.36), p=0.016]. Circulating bacterial DNA profiles associated with male gender and cirrhosis severity were different from those observed for HCC and showed considerable overlap in significant taxa. These included enrichment of the lineage Gammaproteobacteria, Enterobacterales, and Rheinheimera. CONCLUSIONS: The identified circulating bacterial DNA signatures may have utility in personalized approaches to HCC surveillance in MASLD patients.

摘要

背景:需要预测性生物标志物来识别代谢功能障碍相关脂肪性肝病(MASLD)患者中患肝细胞癌(HCC)风险较高的个体。我们的研究旨在确定循环细菌DNA的检测是否与肝硬化的MASLD患者的HCC发生有关。 方法:我们建立了一个多中心前瞻性队列,纳入通过对比增强磁共振成像监测HCC的肝硬化患者。在一项巢式队列研究中,我们对从151例肝硬化的MASLD患者收集的343份纵向血浆样本中提取的游离DNA进行了16S rRNA测序。在这151例患者中,25例在随访期间发生了HCC。 结果:采用计算机去污染方法后,循环细菌DNA谱的变化与HCC发生、肝硬化严重程度和男性性别显著相关。许多鉴定出的分类群是众所周知的与人类相关的细菌。随访期间发生HCC的患者在冢村菌属和拟杆菌属中富集,而嗜盐碱杆菌属减少。在调整了肝硬化严重程度和男性性别后,鉴定出的细菌与HCC发生之间的关联仍然存在。酸杆菌门、冢村菌属和葡萄球菌科在诊断前12个月内对HCC的预测有显著改善[酸杆菌门:比值比(AOR)=2.87(1.36 - 6.04),p = 0.006;冢村菌属:AOR = 2.80(1.34 - 5.85),p = 0.006;葡萄球菌科:AOR = 2.52(1.19 - 5.36),p = 0.016]。与男性性别和肝硬化严重程度相关的循环细菌DNA谱与HCC观察到的不同,并且在显著分类群中显示出相当大的重叠。这些包括γ-变形菌纲、肠杆菌目和莱茵海默菌属的富集。 结论:鉴定出的循环细菌DNA特征可能有助于MASLD患者HCC监测的个性化方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9203/12150986/a6b2f3a9c6c6/hc9-9-e0722-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9203/12150986/3fa9d474f9b7/hc9-9-e0722-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9203/12150986/7760e74adecc/hc9-9-e0722-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9203/12150986/5960258c3fdb/hc9-9-e0722-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9203/12150986/f96d5250e9ed/hc9-9-e0722-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9203/12150986/a6b2f3a9c6c6/hc9-9-e0722-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9203/12150986/3fa9d474f9b7/hc9-9-e0722-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9203/12150986/7760e74adecc/hc9-9-e0722-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9203/12150986/5960258c3fdb/hc9-9-e0722-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9203/12150986/f96d5250e9ed/hc9-9-e0722-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9203/12150986/a6b2f3a9c6c6/hc9-9-e0722-g005.jpg

相似文献

[1]
Blood bacterial DNA signatures in a prospective cohort of patients with MASLD cirrhosis.

Hepatol Commun. 2025-6-9

[2]
Serum levels of total bile acids are associated with an increased risk of HCC in patients with cirrhosis.

Hepatol Commun. 2024-10-10

[3]
High SAFE scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction associated steatotic liver disease.

Clin Mol Hepatol. 2025-1-6

[4]
Adding salt to foods and risk of metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases.

Eur J Nutr. 2025-6-21

[5]
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.

Clin Orthop Relat Res. 2025-1-1

[6]
Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.

Health Technol Assess. 2007-9

[7]
Contrast-enhanced ultrasound using SonoVue® (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis.

Health Technol Assess. 2013-4

[8]
Higher Pre-Operative Non-Invasive Fibrosis Scores are not Associated with Surgical Outcomes in Patients with MASLD Undergoing Metabolic and Bariatric Surgery.

Can Liver J. 2025-2-12

[9]
Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease.

Cochrane Database Syst Rev. 2015-1-22

[10]
Validation of FIB-4 for the Diagnosis of Liver Cirrhosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.

Can Liver J. 2025-2-12

本文引用的文献

[1]
Gut Microbiome and Hepatic Transcriptomic Determinants of HCC Development in Mice with Metabolic Dysfunction-Associated Steatohepatitis.

J Hepatocell Carcinoma. 2024-10-3

[2]
Protection against fibrosis by a bacterial consortium in metabolic dysfunction-associated steatohepatitis and the role of amino acid metabolism.

Gut Microbes. 2024

[3]
Metabolomics biomarkers of hepatocellular carcinoma in a prospective cohort of patients with cirrhosis.

JHEP Rep. 2024-5-15

[4]
Vaccines and monoclonal antibodies to prevent healthcare-associated bacterial infections.

Clin Microbiol Rev. 2024-9-12

[5]
Mycolyltransferase is important for biofilm formation and pathogenesis of keratitis.

Emerg Microbes Infect. 2024-12

[6]
Characterization of tumor microbiome and associations with prognosis in intrahepatic cholangiocarcinoma.

J Gastroenterol. 2024-5

[7]
Molecular mechanisms in MASLD/MASH-related HCC.

Hepatology. 2024-2-13

[8]
Cross talk between the liver microbiome and epigenome in patients with metabolic dysfunction-associated steatotic liver disease.

EBioMedicine. 2024-3

[9]
Disruption of gut barrier integrity and host-microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus.

Gut Microbes. 2024

[10]
Effect of Mycolic Acids on Host Immunity and Lipid Metabolism.

Int J Mol Sci. 2023-12-28

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索